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Investigation of intra-amniotic erythromycin administration as a treatment 
for intrauterine Ureaplasma infection using the pregnant sheep model. 
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Introduction: Ureaplasma species are the organisms most frequently associated 
with intrauterine infection in cases of early preterm birth. Clinically, maternally 
administered erythromycin is the standard antibiotic used for the treatment of 
Ureaplasma infections during pregnancy, although it is largely ineffective. This is 
most likely due to poor transfer from maternal to fetal compartments. The aim of 
this study was to determine the antimicrobial efficacy of administering erythromycin 
maternally (IM) and intra-amniotically (IA) in a sheep model of intra-uterine 
ureaplasma infection.  
 
Methods: At 55 d of gestation (term=150 d) pregnant ewes were inoculated intra-
amniotically with erythromycin-sensitive Ureaplasma parvum serovar 3 (n=28). At 
116 d ewes were allocated to the following treatment groups: 1) maternal IM and IA 
saline injections (n=8); 2) maternal IM erythromycin (500 mg, every 8 hours for 3 
days) injections with a single IA erythromycin injection (3.2 mg per kg estimated 
fetal weight) (n=10) or 3) maternal IM plus 3 IA erythromycin injections 48 h apart 
(n=10). At 125 d fetuses were delivered by Caesarean section and tissues/amniotic 
fluid specimens collected for Ureaplasma culture and DNA extraction for PCR. 
 
Results: Amniotic fluids from all Ureaplasma-inoculated animals were positive for 
Ureaplasma DNA by qualitative PCR prior to delivery. In saline-treated controls 7/8 
(88%) were positive for Ureaplasma infection by either microbiological culture or 
quantitative real-time PCR; antibiotic treatment reduced this to 3/9 (33%) and 3/10 
(30%) in the two erythromycin groups (P<0.05 vs. controls). Antibiotics reduced the 
presence of Ureaplasma DNA in the fetal membranes from 75% (6/8) in the controls 
to 36.8% (7/19) in the combined treatment groups (P>0.05). 
 
Conclusion: Combined IA and maternal IM erythromycin treatment may be an 
effective modality for treatment of intrauterine Ureaplasma infection, although 
complete eradication was not achieved in this study; this may be due to reinfection 
from reservoirs in fetal tissues. Repeat IA administration of erythromycin did not 
increase therapeutic efficacy. 
